25892-94-8

Basic information

• Product Name: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone
• Synonyms: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone;1-(4-(benzyloxy)-3,6-dihydroxy-2-methoxyphenyl)ethan-1-one
• CAS NO: 25892-94-8
• Molecular Formula: C₁₆H₁₆O₅
• Molecular Weight: 288.29524
• Mol File: 25892-94-8.mol
• Article Data: 4

Chemical Properties

• Melting Point: 161-162 °C
• Boiling Point: 517.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.272±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.37±0.50(Predicted)
• CAS DataBase Reference: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone(25892-94-8)
• EPA Substance Registry System: 1-(4-(benzyloxy)-3,6-dihydroxy-2-Methoxyphenyl)ethanone(25892-94-8)

Safety Data

• Hazardous Substances Data: 25892-94-8(Hazardous Substances Data)

Usage

Preparation

Obtained from 4-(benzyloxy)-2-hydroxy-6- methoxy-acetophenone by persulfate oxidation (Elbs reaction).

Upstream product

• 681294-57-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethanone 
• 110506-85-9 7-(benzyloxy)-5-hydroxy-2-phenyl-4H-chromen-4-one 
• 480-40-0 5,7-dihydroxy-2-phenyl-chromen-4-one 
• 100-39-0 benzyl bromide 
• 39548-89-5 1-(4-(benzyloxy)-2-hydroxy-6-methoxyphenyl)ethan-1-one 
• 77-98-5 tetraethylammonium hydroxide 
• 3602-54-8 4,6-dihydroxy-2-methoxyacetophenone 
• 480-66-0 2,4,6-trihydroxyacetophenone 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 

Downstream Products

• 25892-95-9 1-(4-(benzyloxy)-6-hydroxy-2,3-dimethoxyphenyl)ethan-1-one 
• 40983-99-1 2-(3,4-dimethoxyphenyl)-7-hydroxy-5,6-dimethoxy-4H-chromen-4-one 
• 22368-21-4 eupatilin 
• 52378-70-8 (E)-1-(4-Benzyloxy-6-hydroxy-2,3-dimethoxy-phenyl)-3-(3,4-dimethoxy-phenyl)-propenone 
• 52378-71-9 7-(benzyloxy)-2-(3,4-dimethoxyphenyl)-6,7-dimethoxy-4H-chromen-4-one 
• 520-12-7 pectolinarigenin 
• 480-11-5 oroxylin A 
• 1447-88-7 hispidulin 
• 25893-02-1 7-benzyloxy-5,6-dimethoxy-2-(4-methoxy-phenyl)-chromen-4-one 

Relevant articles and documents

Novel compound and composition for prevention, improvement or treatment of fibrosis or non-alcoholic steatohepatitis comprising the same

The present invention relates to a novel compound and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. More specifically, the present invention relates to a novel compound of chemical formula 1 which has an excellent effect for prevention, improvement, or treatment of fibrosis and a composition for prevention, improvement, or treatment of fibrosis or nonalcoholic steatohepatitis comprising the same as an active ingredient. A novel compound of the present invention effectively controls expression of snail and vimentin which are a controlling element of Epithelial Mesenchymal Transition (EMT) and controls activation of EMT, and thus effectively prevents, improves, or treats fibrosis accordingly. Additionally, a novel compound of the present invention has a very excellent pharmacokinetic characteristic, and thus can perform fast drug delivery to the body through oral administration, stably displays an effect in the body, and is secure to use without a big side effect. Moreover, since a novel compound of the present invention can effectively block fibrosis of a hepatic cell, nonalcoholic steatohepatitis can effectively improved or treated.(AA) Chemical formula 1COPYRIGHT KIPO 2018

The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects

1 The functional characterization of hispidulin (4′,5,7-trihydroxy-6- methoxyflavone), a potent benzodiazepine (BZD) receptor ligand, was initiated to determine its potential as a modulator of central nervous system activity. 2 After chemical synthesis, hispidulin was investigated at recombinant GABA A/BZD receptors expressed by Xenopus laevis oocytes. Concentrations of 50 nM and higher stimulated the GABA-induced chloride currents at tested receptor subtypes (α 1-3,5,6β2γ2S) indicating positive allosteric properties. Maximal stimulation at α1β 2γ2S was observed with 10 μM hispidulin. In contrast to diazepam, hispidulin modulated the α6β 2γ2S-GABAA receptor subtype. 3 When fed to seizure-prone Mongolian gerbils (Meriones unguiculatus) in a model of epilepsy, hispidulin (10 mg kg-1 body weight (BW) per day) and diazepam (2 mg kg-1 BW per day) markedly reduced the number of animals suffering from seizures after 7 days of treatment (30 and 25% of animals in the respective treatment groups, vs 80% in the vehicle group). 4 Permeability across the blood-brain barrier for the chemically synthesized, 14C-labelled hispidulin was confirmed by a rat in situ perfusion model. With an uptake rate (Kin) of 1.14 ml min-1 g -1, measurements approached the values obtained with highly penetrating compounds such as diazepam. 5 Experiments with Caco-2 cells predict that orally administered hispidulin enters circulation in its intact form. At a concentration of 30 μM, the flavone crossed the monolayer without degradation as verified by the absence of glucuronidated metabolites.